drugset / Trial / NCT00122863

Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder

NCT00122863

Phase 3 Completed 380 enrolled Eli Lilly and Company Boehringer Ingelheim · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a clinical trial assessing the time to relapse of anxiety symptoms among patients with generalized anxiety disorder who have responded to duloxetine therapy.

Timeline

Start
2005-01
Primary completion
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg
Subject Duloxetine Small molecule 120 mg

Indications